Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

about

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

Item

http://www.wikidata.org/entity/Q45865962

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@en

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@nl

type

Item

label

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@en

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@nl

prefLabel

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@en

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@nl

P1476

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

@en

P2093

Masataka Suzuki

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Adoptive cell transfer as personalized immunotherapy for human cancer.

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Oncolytic viruses: a new class of immunotherapy drugs.

Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.

P304

836-838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMTHE.2017.03.005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28330695

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

5383639

http://www.w3.org/2001/XMLSchema#string